Genmab — November 2018
-
Valuation lige nu er helt hen i hampen, men markedet er rygende skævt
så det :-). Konsensus for Dara salg er 9,2 mia $ eller 61 mia kr. Og Genmab siger at det bliver noget højere -
@Hugo. Det ved vi godt. jeg taler om Dara og hvordan det skal vægtes når peaksales er opnået og det kan ikke være mere end 15 for jo tættere du kommer på patentudløb jo mindre interesse vil der være for Dara - se evt. Gilead som har væet handlet i PE12 - noget tilsvarende vil ske for Dara fremadrettet når der ikke er mere vækspotentiale
-
We conclude that daratumumab has significant activity in highly pretreated RRMM even as a single agent, with an acceptable toxicity profile and survival impact. https://www.ncbi.nlm.nih.gov/pubmed/30397362
-
The NMA showed that daratumumab plus Vd (DVd) provided a significant advantage in prolonging progression-free survival. Similar trends were observed for overall survival and overall response. Across all outcomes, DVd had the highest probability of being the best treatment. These findings suggest that DVd may provide superior clinical outcomes for RRMM patients suitable for IMiD-free regimens. https://www.ncbi.nlm.nih.gov/pubmed/30407092
-
-
http://gabionline.net/Generics/News/Alvogen-receives-European-approval-for-generic-lenalidomide her en en artikel der netop nævner marts 20
22 -
Og så fik AB kørt os i minus.. Positivt at det nærmest kun er dem der sælger i dag, men til gengæld har de godt nok solgt mange.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind